Skip to main content
Clinical Trials/NCT04344210
NCT04344210
Completed
Not Applicable

Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial

Federal University of Rio Grande do Sul1 site in 1 country149 target enrollmentApril 17, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID
Sponsor
Federal University of Rio Grande do Sul
Enrollment
149
Locations
1
Primary Endpoint
Variation in HbA1c levels
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

INTRODUCTION In critical situations, such as the current COVID 19 pandemic, themes of fear, uncertainty and stigmatization are common and constitute barriers to appropriate medical and mental health interventions. These challenges, when faced by those who live with a chronic disease, such as diabetes mellitus (DM), can negatively influence quality of life and adherence to treatment, compromising the control of the disease.

OBJECTIVES The present study aims to investigate the effectiveness of a tele-intervention during the COVID-19 pandemic in improving glycemic control, lipid profile, blood pressure levels and parameters of medication adherence, mental well-being and sleep quality in patients with type 1 DM and type 2 DM.

METHODS A randomized clinical trial will be carried out with patients with a previous diagnosis of type 1 DM and type 2 DM, who are registered at the Hospital de Clínicas de Porto Alegre (HCPA). Inclusion criteria will be age greater than or equal to 18 years, collection of HbA1c in the HCPA laboratory in January, February or March 2020 and availability to receive weekly phone calls. Patients will be randomized, stratified by type of diabetes, in two groups: G1: participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the social distancing period ; G2: participants will receive the usual care. The primary outcome assessed will be the variation in HbA1c levels comparatively between groups, with or without a tele-guided strategy, after four months of social distancing (or as long as the recommendation of social distancing measures remains). Secondary outcomes will include experiencing confirmation of COVID-19 infection, variation in lipid profile, blood pressure levels and variation in parameters of emotional distress related to diabetes, eating disorders, medication adherence, symptoms minor psychiatric disorders and altered sleep patterns, which will be evaluated with specific and validated scales. According to the sample calculation, 150 patients will be included in the study (92 with type 2 DM and 58 with type 1 DM). Analysis by intention to treat will be performed separately for patients with type 1 DM and with type 2 DM.

SCHEDULE The proposed experiment will start immediately after approval of this project by the research ethics committee. The duration of the proposed intervention is 4 months (or as long as the recommendation of social distancing measures remains. This means that the study may be completed before or after that period, based on national recommendations for social distancing in Brazil), with a data analysis plan and publication of the results until September 2020.

Registry
clinicaltrials.gov
Start Date
April 17, 2020
End Date
September 20, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Federal University of Rio Grande do Sul
Responsible Party
Principal Investigator
Principal Investigator

Janine Alessi

Master Student

Federal University of Rio Grande do Sul

Eligibility Criteria

Inclusion Criteria

  • Type 1 diabetes mellitus or type 2 diabetes mellitus;
  • Age greater than or equal to 18 years;
  • HbA1c assessed in January, February or March 2020;
  • Availability to receive weekly phone calls

Exclusion Criteria

  • Any severe cognitive limitation that prevents the necessary interaction to carry out this study (advanced dementia, deafness, dysarthria, aphasia);
  • Do not present a telephone record in an electronic medical record;

Outcomes

Primary Outcomes

Variation in HbA1c levels

Time Frame: 4 months (or as long as the recommendation of social distancing measures remains)

Variation in HbA1c levels comparatively between groups after the period of social distancing measures.

Secondary Outcomes

  • Variation in blood pressure levels(4 months (or as long as the recommendation of social distancing measures remains))
  • Comparison of eating disorders between groups(4 months (or as long as the recommendation of social distancing measures remains))
  • Comparison of sleep pattern changes between groups(4 months (or as long as the recommendation of social distancing measures remains))
  • COVID-19 infection(4 months (or as long as the recommendation of social distancing measures remains))
  • Variation in lipid profile(4 months (or as long as the recommendation of social distancing measures remains))
  • Comparison of adherence to the proposed clinical treatment between groups(4 months (or as long as the recommendation of social distancing measures remains))
  • Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups(4 months (or as long as the recommendation of social distancing measures remains))
  • Comparison of minor psychiatric disorders between groups(4 months (or as long as the recommendation of social distancing measures remains))

Study Sites (1)

Loading locations...

Similar Trials